Brief: Philogen Says Entered Into Global Licensing Agreement For Commercializing Fibromun
01/10/2024 04:05
Sept 30 (Reuters) - Philogen SpA PHIL.MI :
* PHILOGEN SPA - ANNOUNCED THAT THEY HAVE ENTERED INTO A
GLOBAL
LICENSING AGREEMENT FOR COMMERCIALIZING PHILOGEN'S SPECIALTY
PRODUCT, FIBROMUN
* PHILOGEN SPA - SUN PHARMA WILL HAVE EXCLUSIVE WORLDWIDE
RIGHTS
TO COMMERCIALISE FIBROMUN
* PHILOGEN SPA - OTHER FINANCIAL TERMS WERE NOT DISCLOSED
Source text for Eikon: ID:nINF57kRzF
Further company coverage: PHIL.MI
((Reuters.briefs@thomsonreuters.com;))
Recent news on Philogen
See all newsBrief: Philogen H1 Net Loss €19.6 Mln
Brief: Philogen Resubmits To EMA Marketing Authorization Application For Nidlegy
Brief: Sun Pharma Says Partner Philogen's Phase II Flash Study In Soft Tissue Sarcoma Did Not Meet Primary Endpoint
Brief: Philogen Reports FY EBITDA Of EUR 261.6 Million
Brief: Philogen H1 Net Loss EUR 14,894